By Joyce Tait
Successful and sustainable businesses in the Regenerative Medicine industry need to incorporate strategies to address key factors beyond individual business boundaries. These include legal, ethical and financial frameworks, distribution and logistics, and end users willingness to adopt and ability to pay. Business models need to be well adapted to the needs of this market and wil vary depending on whether the end product is a cellular therapy, a delivery system for cells, genes or small molecules or enabling tools and technologies for stimulating endogenous repair. The value systems for each of these types of products are likely to have unique features but will also need to be compliant with global regulatory and legal frameworks.
Showing posts with label life sciences. Show all posts
Showing posts with label life sciences. Show all posts
Friday, 25 June 2010
Thursday, 14 May 2009
Scientific experiment confirms what most people thought, a few scientists quite pleased
By Ann Bruce, Innogen Research Fellow
The social science community often critiques life scientists for over-promising what their work will deliver. This was a strong theme from a recent stem cell conference, ‘Beyond Pattison’.
But what can we really expect life scientists to do?
They are expected to produce academically “excellent science” and to justify the relevance and value of this to publics – who are, after all, funding the research.
No wonder then that the life scientists might talk about their research in terms of potential therapies for say, multiple sclerosis rather than say, understanding how a particular signalling factor is determining whether a cell differentiates or not. No doubt there are occasions when individual scientists over-state their case or when newspaper headlines promise unrealistic cures but I for one am not surprised that natural scientists justify their research, which may be a long-way from producing applications, in terms of cures. We as a society have asked them to do so.
The question surely is not whether life scientists sometimes apparently promise one thing and deliver something else but when does this matter?
As a society we demand that scientists tell us why they are doing the research but we should not do this naively. Instead we need to do this with our eyes open to the myriad possibilities that could arise from the research and the complexity and timescale of the process needed to move from research finding to clinical treatment.
The social science community often critiques life scientists for over-promising what their work will deliver. This was a strong theme from a recent stem cell conference, ‘Beyond Pattison’.
But what can we really expect life scientists to do?
They are expected to produce academically “excellent science” and to justify the relevance and value of this to publics – who are, after all, funding the research.
No wonder then that the life scientists might talk about their research in terms of potential therapies for say, multiple sclerosis rather than say, understanding how a particular signalling factor is determining whether a cell differentiates or not. No doubt there are occasions when individual scientists over-state their case or when newspaper headlines promise unrealistic cures but I for one am not surprised that natural scientists justify their research, which may be a long-way from producing applications, in terms of cures. We as a society have asked them to do so.
The question surely is not whether life scientists sometimes apparently promise one thing and deliver something else but when does this matter?
As a society we demand that scientists tell us why they are doing the research but we should not do this naively. Instead we need to do this with our eyes open to the myriad possibilities that could arise from the research and the complexity and timescale of the process needed to move from research finding to clinical treatment.
Subscribe to:
Posts (Atom)